Bml Capital Management, LLC 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Bml Capital Management, LLC disclosed 15 US equity positions worth $175.1m in its Q2 2026 13F filing. The largest position was ACRS at 36.2% of the reported book, followed by AVIR and ENGN. Against the Q1 2026 filing, it opened 1 new position, added to 4 and reduced 3 among the top 15 holdings.
What did Bml Capital Management, LLC own in Q2 2026? Top 15 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 36.2% | $63.3m | 11,975,000 | -16% | reduced |
| 2 | AVIR ATEA PHARMACEUTICALS INC | Healthcare | 18.5% | $32.3m | 6,952,330 | -2% | reduced |
| 3 | ENGN ENGENE THERAPEUTICS INC | 6.6% | $11.5m | 6,669,908 | – | new | |
| 4 | KHC KRAFT HEINZ CO | Consumer Defensive | 6.3% | $11.0m | 465,000 | 272% | added |
| 5 | OM OUTSET MED INC | 6.2% | $10.9m | 2,519,701 | 32% | added | |
| 6 | KMX CARMAX INC | Consumer Cyclical | 5.2% | $9.1m | 172,500 | 11% | added |
| 7 | TLYS TILLYS INC | Consumer Cyclical | 5.2% | $9.0m | 2,150,000 | 0% | held |
| 8 | PMVP PMV PHARMACEUTICALS INC | Healthcare | 4.1% | $7.1m | 5,330,000 | 0% | held |
| 9 | TIL INSTIL BIO INC | 2.8% | $5.0m | 645,600 | 0% | held | |
| 10 | TGT TARGET CORP | Consumer Defensive | 2.8% | $4.9m | 37,500 | 0% | held |
| 11 | ORMP ORAMED PHARMACEUTICALS INC | 2.4% | $4.2m | 866,269 | -73% | reduced | |
| 12 | JANX JANUX THERAPEUTICS INC | Healthcare | 1.4% | $2.4m | 154,961 | 0% | held |
| 13 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 1.0% | $1.8m | 1,546,137 | 0% | held |
| 14 | CNTB CONNECT BIOPHARMA HLDGS LTD | 0.8% | $1.4m | 573,287 | 40% | added | |
| 15 | IMA IMAGENEBIO INC | 0.7% | $1.2m | 200,730 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.